NDA 015034 · Avion Pharms
Ponstel
Mefenamic Acid · Oral
NovelLast checked: Nov 20, 2026Latest source record: Dec 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1967
Mar 28, 1967
Approved uses
1
Original approval plus efficacy supplements
Registered trials
17
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 28, 1967 Original approval · Type 1 - New Molecular Entity Medication Guide
1 products under this application
- PONSTEL · MEFENAMIC ACID 250MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mefenamic Acid" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With DysmenorrheaPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02183025 · 337 participants · Start Jan 1998 · Primary completion Apr 1999
Drug: Meloxicam 7.5 mg; Meloxicam 15 mg and 4 more · For: Dysmenorrhea
- Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic CausePivotal-lookingCompleted
Assiut UniversityAcademic, hospital or other
NCT02943655 · 240 participants · Start Nov 1, 2017 · Primary completion Oct 10, 2020
Drug: combined contraceptive pills (microcept); medroxyprogesterone acetate (progest) and 1 more · For: Improve Quality of Life; Heavy Menstrual Bleeding
Sites: Assiut, Egypt
- Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01295294 · 187 participants · Start Mar 2011 · Primary completion Dec 2011
Drug: Tranexamic acid; Mefenamic acid and 2 more · For: Uterine Hemorrhage
Sites: Aalborg, Denmark; Århus C, Denmark; København NV, Denmark · 12 sites in all
- Efficacy of Different Drugs to Control Post Root Canal Treatment PainPivotal-lookingCompleted
University of KhartoumAcademic, hospital or other
NCT02417337 · 185 participants · Start Aug 2012 · Primary completion Aug 2014
Drug: Paracetamol; Ibuprofen and 2 more · For: Pain; Postoperative Pain; Irreversible Pulpitis
Sites: Khartoum, Sudan
- Efficacy of Mefenamic Acid and Hyoscine for Pain Relief During Saline Infusion Sonohysterography in Infertile WomenPivotal-lookingStatus unknown
Mahidol UniversityAcademic, hospital or other
NCT01060696 · 138 participants (planned) · Start Jan 2009 · Primary completion Mar 2010
Drug: Mefenamic acid or Hyoscine or placebo · For: Infertility
Sites: Bangkok, Thailand
- Management of Abnormal Uterine BleedingPivotal-lookingCompleted
EgymedicalpediaIndustry
NCT06369012 · 130 participants · Start Mar 1, 2024 · Primary completion Sep 1, 2024
Drug: Mefenamic acid 500 mg · For: Abnormal Uterine Bleeding
Sites: Cairo, Egypt
- Preemptive Analgesia for Primary DysmenorrhoeaPivotal-lookingCompleted
Hanan NabilAcademic, hospital or other
NCT03323671 · 84 participants · Start Aug 1, 2017 · Primary completion Dec 1, 2017
Drug: preemptive mefenamic acid; mefenamic acid · For: Primary Dysmenorrhea
Sites: Al Mansurah, Egypt
- DLBS1442 for The Treatment of Pain in Patients Suspected EndometriosisPivotal-lookingCompleted
Dexa Medica GroupIndustry
NCT01942122 · 60 participants · Start Oct 2015 · Primary completion Feb 2021
Drug: DLBS1442 100; Mefenamic acid and 1 more · For: Endometrioma; Visual Analogue Pain Scale: Moderate or Severe Pain
Sites: Jakarta Pusat, Indonesia; Jakarta, Indonesia · 3 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exercise for dysmenorrhoea.
Armour M, Ee CC, Naidoo D, et al. · Cochrane Database Syst Rev 2019 · Systematic Review
- A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation.
Arruda MP, Lima RV, Hira S, et al. · Am J Ophthalmol 2024 · Meta-Analysis, Systematic Review
- Mefenamic acid.
· Br Med J 1966 · Clinical Trial
- Treatment of dysmenorrhea.
Budoff PW · Am J Obstet Gynecol 1977 · Clinical Trial, Letter
- Management of bleeding irregularities during contraceptive implant use: A systematic review.
Cohen MA, Snyder EM, Curtis KM, et al. · Contraception 2026 · Systematic Review
- Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine-device use.
Christelle K, Norhayati MN, Jaafar SH · Cochrane Database Syst Rev 2022 · Research Support, N.I.H., Extramural, Systematic Review
Sponsor: Avion Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.